International Journal on Science and Technology (IJSAT)
E-ISSN: 2229-7677 ● Website: www.ijsat.org ● Email: editor@ijsat.org

An Overview of the Development and Validation of Bioanalytical Methods and Their Use in Pharmacy

Mayur S. Ingle[1], Shraddha K. Khatri[2]

[1,2]Anuradha College of Pharmacy

ABSTRACT

According to this review article, bioanalytical techniques are frequently employed to measure medications and their metabolites in plasma matrices, and these techniques ought to be used in both nonhuman and human clinical research. Drugs and their metabolites are quantitatively estimated using a bioanalytical approach in biological media, which is crucial for estimating and interpreting pharmacokinetic, toxicokinetic, and bioequivalence data research. Sample analysis, method development, and method validation are the main bioanalytical functions. To determine the degree to which environmental, matrix, or procedural factors may impede the estimation of analyte in the matrix from the time of setup until the time of analysis, each stage in the procedure must be examined. Drugs in the body can be bioanalyzed using methods like liquid chromatography combined with double mass spectrometry (LCMS-MS) and high pressure liquid chromatography (HPLC). Every instrument has advantages and disadvantages of its own. The bioanalysis of small and big compounds using LC/MS/MS has been the primary application of chromatographic techniques such as gas chromatography and HPLC. Accuracy, Linearity, Among the often utilized parameters are precision, selectivity, sensitivity, repeatability, and stability. We suggest adding additional information about the development and validation parameters of bioanalytical methods in this review article. This would help with quality assurance in determining the drug, concentration, and its metabolite.

1. INTRODUCTION

Sample preparation and sample separation are the two primary components in the development of bioanalytical methods. In bioanalysis, sample preparation is crucial to obtaining a clean extract with good extraction efficiency. The range of analyte concentrations also influences the detector selection. The development and discovery of new drugs depend on bioanalytical testing. Pharmacokinetics and toxic kinetic studies are evaluated using bioanalytical methods to quantify medicines and their metabolites or associated biomarkers in biological fluids. These techniques can be used to investigate clinical pharmacology and toxicity in humans. Why is this important? It is related to the concentration of the medication. The length of time a drug remains in the body and its effects during that time are influenced by its concentration. The medication won't have the intended effects if the concentration is too low. [1] It might become harmful to the system if it is very high. One of the most important aspects of medication research is figuring out the concentration of the drug after injection or consumption. It is impossible to develop a medicine without this understanding. What makes it practical is bioanalytical testing. [2]

2. BIOANALYTICAL TESTING: WHAT IS IT?

The process of detecting and measuring medications and metabolites in a variety of biological matrices, including blood, plasma, serum, cerebrospinal fluid, saliva, and urine, is known as bioanalytical testing, or bioanalysis. For your program to proceed smoothly from discovery to IND submission and beyond, it is essential that these data be collected at every stage of the drug development process. • Learning Bioanalysis: In vivo and in vitro sample analysis, hazardous effects, biomarker assays, dose, and fit-for-purpose non-GLP sample analysis.

• Preclinical Bioanalysis: GLP toxicokinetics (TK) and pharmacokinetics (PK) sample analysis, as well as generic bioequivalence sample analysis made possible by IND.

•Clinical Bioanalysis: analysis of GxP clinical samples.

Researchers must produce extremely accurate data in order to advance from one stage of the drug development process to the next and make well-informed decisions. But how does it all really operate? The first step is to find biomarkers. To locate or detect a medication in the system within different biological matrices, a precise biomarker can be used to determine the drug's concentration. Although the phrase "bioanalysis" seems wide, in reality it refers to hundreds of proven techniques that are specifically tailored to the kind of molecule and chemical that requires analysis. Bioanalytical Method Validation is the term for this. [3]

3. BIOANALYTICAL METHOD VALIDATION: WHAT IS IT?

To provide reliable, useable data, researchers must create, qualify, and validate bioanalysis techniques throughout the drug development process and then transfer them from one step to the next. Since proper validation promotes data dependability, assay performance, and PK and TK study preparation, it is essential to every drug development program. [4] To assist medication developers in guaranteeing the bioanalytical quality of their results, the FDA published industry guidelines on bioanalytical technique validation. Similarly, M10, a multidisciplinary guideline to regulate the validation of bioanalytical methods, was released by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH). Bioanalytical techniques need to be appropriate for their specific use. Researchers don't need to start from scratch because there are hundreds of nonproprietary methods available. [5]

Certain techniques rely on:

•Type of molecule: Novel modality drug, small or large molecule.

•Compound: A particular molecular formula under investigation that might influence particular genes or proteins implicated in a disease.

•Calibration range: The maximum and lower bounds of an analyte in the sample to guarantee that the analytical process has an appropriate degree of linearity, accuracy, and precision. •The biological matrix, which includes serum, plasma, and blood.

• Anticoagulant, if applicable: Substances administered during blood collection that prevent blood from coagulating after collection. Not to mention the various drug development processes you have to worry

about, method development and validation is a huge job in and of itself. Following instructions is so essential, which is why many medication researchers collaborate with specialized labs to develop and validate bioanalytical methods. [6]

4. COLLABORATING WITH A PARTNER IN BIOANALYTICAL TESTING

Bioanalytical testing partners are usually used by large pharmaceutical corporations, which frequently have shorter deadlines. Third-party partners offer specific benefits that speed up the development process, even if pharmaceutical corporations may possess the resources and expertise to create their own techniques. These are the largest.

1. Regulatory perspectives

Labs that specialize in bioanalytical testing frequently have greater access to regulations and the queries or requests that regulatory bodies may make. Partner companies are better able to adhere to regulations and adjust to changes thanks to this regulatory expertise.
Regulations are a major problem for toxicity research at the discovery stage. But once you're in the IND stage, every little thing matters. This is why it's so crucial to comprehend regulatory instructions. You must be able to trace back the drug's concentration, technique, incubation, and other details in case authorities have issues. [7]

2. Capabilities for automation

It takes a lot of time and effort to get a medicine onto the market. Process automation during bioanalytical testing can improve analytics quality, timeliness, and assay accuracy.
For instance, manual PK validation assays can take up to two weeks to complete. That can be reduced to a few days with automation. Additionally, it facilitates the production of higher-quality data and assays, assisting researchers in adhering to regulatory requirements.
Look for a partner who has automation capabilities, as not all bioanalytical testing labs have these.

3. Comprehensive experience & method library creating novel approaches

To get bioanalytical methods properly, a lot of evaluation and careful regulatory scrutiny are needed. Proficient pharmaceutical firms probably own a collection of verified bioanalytical techniques. The most comprehensive libraries, however, will belong to partners who have collaborated with hundreds of businesses and created hundreds of verified, nonproprietary techniques on thousands of samples. Work will be completed more quickly and deadlines won't be missed if you have additional techniques at your disposal. Additionally, an experienced partner will be far more ready to assist if you need to develop a proprietary method or a method for innovative molecules. [8]

5. BIOANALYTICAL METHOD

Some of the following bioanalytical method:

- Extraction method
- Protein precipitation
- Chromatography method

• Ligand binding assay (LBA).

Extraction method

Liquid-liquid extraction: It is founded on the ideas of analyte molecule partitioning equilibrium between the organic and aqueous phases (the sample) and differential solubility. In most cases, liquid-liquid extraction entails moving a material from one liquid phase to another [9]. These days, sophisticated and enhanced techniques such as liquid phase micro extraction, supported membrane extraction, and single drop liquid phase micro extraction have supplanted liquid extraction [10].

SPE: SPE is a selective sample preparation technique in which the analyte is eluted selectively after being bonded onto a solid support and interferences are removed. With so many sorbent options, SPE is an extremely effective method.

a) Conditioning: An organic solvent that solvates the sorbent's functional groups and serves as a wetting agent on the packing material activates the column. To activate the column for appropriate adsorption mechanisms, water or an aqueous buffer is supplied.
b) Loading of the sample: The sample enters the column by gravity feed, pumping, or vacuum aspiration once the pH has been adjusted.
c) Cleaning: The analyte is retained while matrix interferences are eliminated.
d) Elution: As much of the residual interference as feasible is eliminated by distributing the analyte-sorbent interactions by an appropriate solvent. [11–14].

Protein precipitation

Adding a salt, an organic modernizer, or altering the pH can all cause precipitation, which affects how soluble the proteins are. After centrifuging the samples, the supernatant can either be added to the HPLC system or dried off and dissolved in an appropriate solvent. The sample's concentration is then attained. In contrast to SPE, the precipitation approach has certain advantages as a cleanup procedure [15]. Little amounts of organic modifier or other solvents are used, and it takes less time. However, there are drawbacks as well; the samples frequently contain protein particles, the sample cleanup procedure is non-selective, and there is a chance that endogenous chemicals or other medications could limit the reversed phase HPLC system.

To create a clean extract, SPE is frequently used in conjunction with the protein precipitation process. [16] Because it can yield a clean supernatant that is suitable for direct addition into HPLC, methanol is typically preferred among organic solvents. Another substitute for acid organic solvent precipitation is salt. We refer to this process as salt-induced precipitation. Proteins agglomerate and precipitate out of solutions with higher salt concentrations [17,18].



Fig. Bioanalytical Method

Chromatography method

Chromatographic technique Standards of reference Calibration standards and quality control samples (QCs) tainted with reference standards are used to analyze medications and their metabolites in biological fluids. Study results may be impacted by the purity of the reference standard used to create the spiked samples. Therefore, solutions of known concentrations must be prepared using authenticated analytical reference standards of established identity and purity. The reference standard and the analyte should, if at all possible, match. If this isn't feasible, a known-purity, predictable chemical form (such as an ester, salt, or free base or acid) can be utilized.

Typically, three kinds of reference standards are employed:

• Approved benchmarks (such as USP compendial standards).

• Reference standards that are commercially supplied and acquired from a reliable commercial source.
• Additional materials that have been custom-synthesised by an analytical laboratory or other noncommercial organization and have been proven to be pure.

For every reference and internal standard (IS) utilized, the source, lot number, expiration date, documentation of analyses, if any, and/or internally or externally generated proof of authenticity and purity should be provided. Stock solutions prepared using this lot of standard should not be utilized if the reference or IS has expired unless purity has been restored [19,20].

Ligand binding assay (LBA)

LBA Many of the above-discussed bioanalytical validation metrics and principles also apply to microbiological and LBA. These assays come in a range of design configurations with distinctive characteristics that should be taken into account when validating the procedure.



Fig. Bioanalytical Method Separation

6. METHOD DEVELOPMENT

Drug development and chemistry manufacturing and controls (CMC) depend heavily on the development and validation of methods. Making sure that the techniques used to assess the identification, purity, potency, and stability of medications are precise, accurate, and dependable is the aim of method development and validation. In the process of developing new drugs, analytical techniques are essential for guaranteeing the efficacy, safety, and quality of pharmaceutical goods. The process of choosing and refining analytical techniques to quantify a particular property of a drug substance or drug product is known as analytical method development. In order to measure the target property within reasonable bounds of accuracy and precision, this procedure entails a methodical evaluation and selection of appropriate techniques that are robust, sensitive, and specific. [21]

7. VALIDATION

Method validation is the process used to confirm that the analytical procedure employed for a specific test is suitable for its intended use. Results from method validation can be used to judge the quality, reliability, and consistency of analytical results; it is an integral part of any good analytical practice. It is the process of defining an analytical requirement and confirming that the method under consideration has performance capabilities consistent with what the application requires. The use of equipment that is within specification, working correctly, and adequately calibrated is fundamental to the method validation process. Likewise, the operator carrying out the studies must be competent in the analysis under study and have sufficient knowledge of the method/analysis to conclude from the observations as the validation work proceeds. Quite often method validation evolves from method development and so the two activities are often closely tied, with the validation study employing the techniques and steps in the analysis as defined by the method development. [22]

The concept of validation was first proposed by two of the Food And Drug Administration (FDA) officials, Ted Byers and Bud Loftus, in the mid-1970s to improve the quality of pharmaceuticals. Validation is the act of demonstrating and documenting that a process operates effectively. "The United States Food and

Drug Administration (USFDA)guidelines state that the process of validation is the Establishing documented evidence which provides a high degree of assurance that a specific process will consistently produce a product meeting its pre-determined specifications and quality attributes" [23]

"Validation is a process of establishing documentary evidence demonstrating that a procedure, process, or activity carried out in production or testing maintains the desired level of compliance at all stages." In the Pharma industry, it is very important apart from final testing and compliance of the product with the standard that the process adapted to produce itself must ensure that the process will consistently produce the expected results. Here the desired results are established in terms of specifications for the outcome of the process. Qualification of systems and equipment is therefore a part of the process of validation. It is a requirement of food and drug, and pharmaceutical regulating agencies like the FDA's good manufacturing practices guidelines. Since a wide variety of procedures, processes, and activities need to be validated, the field of validation is divided into several subsections including the following,

- Equipment validation
- Facilities validation
- HVAC system validation
- Cleaning validation
- Process Validation
- Analytical method validation
- Computer system validation
- Packaging validation
- Cold chain validation

Similarly, the activity of qualifying systems and equipment is divided into several subsections including the following:

- Design qualification (DQ)
- Component qualification (CQ)
- Installation qualification (IQ)
- Operational qualification (OQ)
- Performance qualification (PQ) [24]

Which four types are important

- Process validation
- Equipment validation
- Cleaning validation
- Computational validation

Reasons of Validation

FDA, or any other food and drugs regulatory agency around the globe not only asks for a product that meets its specifications but also requires a process, procedures, intermediate stages of inspections, and testing adopted during manufacturing are designed such that when they are adopted they produce

consistently similar, reproducible, desired results which meet the quality standard of the product being manufactured, such procedures are developed through the process of validation. This is to maintain and ensure a higher degree of quality of food and drug products. Validation is "Establishing documented evidence that provides a high degree of assurance that a specific process will consistently produce a product meeting its pre-determined specifications and quality attributes." A properly designed system will provide a high degree of assurance that every step, process, and change has been properly evaluated before its implementation. Testing a sample of a final product is not considered sufficient evidence that every product within a batch meets the required specification. [25]

Method development and validation are essential procedures for guaranteeing the accuracy and dependability of analytical techniques, especially in domains such as quality control and pharmaceutical research, to make sure that the techniques employed are appropriate for their intended use.
Method Creation:

• Goal: The process of developing or modifying analytical techniques to precisely and consistently assess particular analytes or sample properties is known as method development.
• Actions:

1. Recognize the sample: Describe the sample matrix and the analyte.
Establish the objectives: Establish what the analysis's goal is.
2. Select an analytical method: Depending on the sample and objectives, choose the proper analytical technique.
3. Optimize the situation: For the best separation and detection, adjust elements such as the detector, mobile phase, and column.

4. Sample preparation: Create an appropriate procedure for getting the sample ready for examination. [26] Verify the procedure to make sure it is operating as intended. As an illustration, consider creating a technique to gauge the amount of a medicine in a formulation or figuring out how pure a chemical molecule is. The process of proving that a developed method is appropriate for its intended use by assessing its performance metrics is known as method validation.

• Crucial Performance Elements:

1. Accuracy: The degree to which the outcomes resemble the actual value.

2. Precision: The degree to which the outcomes of many measurements agree with one another.

3. Linearity: The method's capacity to yield outcomes that are proportionate to the concentration of the analyte.
4. Specificity: The method's capacity to measure just the relevant analyte and not any other chemicals that could interfere.

5. Limit of Detection (LOD): The lowest analyte concentration at which a reliable detection can be made. The lowest analyte concentration that can be accurately measured is known as the Limit of Quantitation (LOQ).
6. Robustness: The method's capacity to withstand minor, intentional changes in its parameters.

7. Ruggedness: The method's capacity to yield comparable outcomes whether used by various operators or in various labs. [27]

Validation Procedure: •
Create a procedure for validation: Clearly state the experimental design, acceptance criteria, performance characteristics, and scope.
• Carry out validation tests: To assess the method's performance parameters, do experiments.
• Record the outcomes: Carefully record the validation data and findings.
• Significance: Validation guarantees that analytical findings are accurate, dependable, and suitable for their intended use, all of which are essential for quality assurance, legal compliance, and well-informed research and development decision-making. [28]



Fig. Steps of analytical method of validation.

8. BIOANALYTICAL AND BIOANALYSIS

A drug development program must include both regulated bioanalysis and the validation of bioanalytical methods. Their technical platforms and laws have changed over time. Chemical-based therapeutic candidates have been analyzed using a variety of technical platforms, including LC-UV, LC-Fluorescence, LC-MS, and LC-MS/MS. Although they have not yet been completely standardized, guidance materials from regulatory authorities worldwide are being updated to reflect the latest technologies. [29] Bioanalysts should carefully compare the physiochemical characteristics of the target analyte, its metabolites, and assay specifications such LLOQ and matrix to the technical platforms that are currently on the market at the beginning of method development. A thorough evaluation of the various parameters that may impact the assay's performance is necessary. The bioanalysts can then move forward with method validation and bioanalysis in compliance with various regulatory requirements and laboratory-specific SOPs after developing a desired technique. Additionally, techniques can be changed in response to new information, such as the identification of a novel metabolite that needs to be monitored, the generation of additional data, such as clinical pharmacokinetic data from a FIH study that may lead to a lower LLOQ, or other unforeseen problems. It must be recognized that the process of developing and validating a method is a continuous one. As drug research advances, a bioanalytical assay has a life cycle and ought to be guided by science. Analyte extraction from biological materials, liquid chromatography to separate target analytes from endogenous components and metabolites that could result in a matrix effect or selectivity problem,

and MS detection often in the form of tandem mass spectrometers to improve assay sensitivity and selectivity are the standard components of bioanalytical techniques. All three components must be considered holistically as a single integrated system when creating a quantitative bioanalytical LC-MS technique, and trade-offs occasionally need to be carefully balanced. The integrity of the analyte must always be considered while extracting samples and performing chromatography. It should be mentioned that certain labile metabolites can affect quantification during sample extraction, chromatography, and MS detection even when they are not being measured. Rarely can biological samples be directly injected onto the LC-MS apparatus. Before LC-MS analysis, the biological matrices must be cleared of the relevant analytes. The goal of extraction is to concentrate the analytes and enhance their detection by removing or minimizing interferences that may co-elute with the analytes and result in matrix effects or quantitation mistakes. The analyte, not the matrix, is the main focus when optimizing the extraction. This implies that a strong matrix effect could also affect an extraction technique that has the highest analyte recovery. The most widely used sample preparation techniques include liquid-liquid extraction (LLE) (solid-phase assisted liquid-liquid extraction), protein precipitation, direct injection, diluted and shoot, and solid-phase extraction (SPE). [30]



Fig. Advantage of Bioanalytical Analysis

9. COMMON BIOANALYTICAL TECHNIQUES:

• Spectroscopy: Analytes in biological samples are frequently identified and quantified using mass spectrometry (MS), Raman spectroscopy, and infrared (IR) spectroscopy.

• Chromatography: Complex mixtures of chemicals in biological samples are separated and analyzed using gas chromatography (GC) and liquid chromatography (LC).

• Microextraction Methods: Analytes are extracted and concentrated from biological samples using liquid-based microextraction (LPME), stir-bar sorptive extraction (SBSE), and solid-phase microextraction (SPME).

• Immunoscience: Proteins and other macromolecules in biological samples can be found and measured using techniques like flow cytometry, western blotting, and ELISA.

• Molecular Biology: DNA and RNA in biological materials are found and examined using PCR and DNA sequencing. [31]

Problems and Prospects for the Future:

• Complexity of the Sample: Because biological samples are intricate matrices, proper sample preparation is essential for precise and trustworthy results.

• Specificity and Sensitivity: Detecting and measuring analytes at low concentrations requires the development of techniques with high sensitivity and specificity.

• Automation and Miniaturization: Creating automated and miniature bioanalytical platforms can save expenses and increase throughput.

• Integration of Bioanalytical Techniques: A more thorough understanding of biological systems can be obtained by combining several bioanalytical techniques.

• New Technologies: Aptamers, DNA walkers, and nanobiosensors are becoming more and more promising instruments for bioanalytical uses. [32]

10. BIOANALYTICAL APPLICATIONS

Drug discovery, development and therapeutic applications depend on the analysis and quantification of substances (drugs, metabolites, and biomarkers) in biological samples. This is known as bioanalytical applications.

• Important Application Domains: 1. Drug Discovery and Development: Bioanalytical techniques are essential for evaluating drug efficacy and safety as well as for evaluating drug absorption, distribution, metabolism, and excretion (ADME). 2. Pharmacokinetics and Pharmacodynamics: Bioanalysis aids in figuring out how medications impact physiological functions and behave in the body throughout time. 3. Toxicology: To determine a substance's toxicity and detect any potential negative consequences, bioanalytical techniques are employed. The discovery and validation of biomarkers, which are useful for early illness detection, diagnosis, and therapy efficacy monitoring, are made possible in large part by bioanalysis. 4. Forensic Analysis and Doping Control: For legal and regulatory reasons, bioanalysis is utilized to find drugs and other compounds in biological samples.

5. Metabolomics: Individual metabolic profiles are studied using bioanalytical techniques, which might reveal information about the causes of disease and possible treatment targets. [33,34]

11. CONCLUSION

In pharmaceutical research and development, bioanalysis and the generation of pharmacokinetic, toxicokinetic, and metabolic data are essential components of the drug discovery and development process. An effort has been made to comprehend and elucidate the development and validation of bioanalytical methods from the perspective of the quality assurance department. This article reports on some of the methods and how validation is done in various scenarios that were encountered during the research sample analysis. To raise the bar and increase acceptance in this field of study, these several crucial development and validation features for bioanalytical methodology have been examined.

REFERENCES

1. Moein MM, El Beqqali A, Abdel-Rehim M. Bioanalytical method development and validation: Critical concepts and strategies. Journal of Chromatography B. 2017 Feb 1;1043:3-1
2. Thompson M, Ellison SL, Wood R. Harmonized guidelines for single laboratory validation of method of analysis. Pure Appl Chem 2008;74(5):835-55.
3. Wood R. How to validate analytical methods. Trends Analyt Chem 2005;18:624-32.
4. Chiu ML, Lawi W, Snyder ST, Wong PK, Liao JC, Gau V. Matrix effects: A challenge toward automation of molecular analysis. J Assoc Lab Autom 2010;15:233-42.
5. Reid E, Wilson ID. Methodological survey in biochemistry and analysis. Analysis for Drug and Metabolites, Including Anti-Infective Agents. Vol. 20. Cambridge, England: Royal Society of Chemistry; 1990. p. 1-57.
6. Surendra B, DeStefano A. Key elements of bioanalytical method validation for small molecules. AAPS J 2007;9(1):109-14.
7. McDowall RD. The role of laboratory information management systems LIMS in analytical method validation. Anal Chim Acta 2007;54:149-58.
8. Vander Heyden Y, Nijhuis A, Smeyers-Verbeke J, Vandeginste BG, Massart DL. Guidance for robustness/ruggedness tests in method validation. J Pharm Biomed Anal 2001;24(5-6):723-53.
9. Swartz ME, Krull IS. Analytical method development and validation. CRC Press; 2018 Oct 3.
10. Gupta V, Jain ADK, Gill NS, Gupta K. Development and validation of HPLC method - a review. Int Res J Pharm Appl Sci. 2012;2(4):17-25.
11. Nikolin B, Imamović B, Medanhodzić-Vuk S, Sober M. High performance liquid chromatography in pharmaceutical analyses. Bosn J Basic Med Sci. 2004; 4(2):5-9. doi:10.17305/ bjbms.2004.3405.
12. Snyder LR, Kirkland JJ, Glajch JL. Practical HPLC method development. John Wiley & Sons; 2012 Dec 3.
13. Rao KR, Kumar KS. Bioanalytical method validation-A quality assurance auditor view point. J Pharm Sci Res 2009;1(3):1-10.
14. Lang JR, Bolton S. A comprehensive method validation strategy for bioanalytical applications in the pharmaceutical industry--1. Experimental considerations. J Pharm Biomed Anal 1991;9(5):357-61.
15. Shah VP. The history of bioanalytical method validation and regulation: Evolution of a guidance document on bioanalytical method validation. AAPS J 2007;9(1):43-7.
16. Buick AR, Doig MV, Jeal SC, Land GS, McDowall RD. Method validation in the bioanalytical laboratory. J Pharm Biomed Anal 1990;8(8-12):629-37.
17. Tiwari G, Tiwari R. Bioanalytical method validation: An updated review. Pharm Methods 2010;1(1):25-38.

18. Mark H. Application of improved procedure for testing linearity of analytical method to pharmaceutical analsysis. J Pharm Biomed Anal 2003;33(1):7-20.
19. Hartmann C, Smeyers-Verbeke J, Massart DL, McDowall RD. Validation of bioanalytical chromatographic methods. J Pharm Biomed Anal 1998;17(2):193-218.
20. Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. Vol. 13. Rockville, MD: U.S Department of Health and Human Services, Food and Drug Administration; 2001. p. 385-94.
21. Karnes HT, Shiu G, Shah VP. Validation of bioanalytical methods. Pharm Res 1991;8(4):421-6.
22. Kringle RO. An assessment of the 4-6-20 rule of acceptance of analytical runs in bioavailability, bioequivalence, and pharmacokinetic studies. Pharm Res 1994;11(4):556-60.
23. Wieling J, Hendriks G, Tamminga WJ, Hempenius J, Mensink CK, Oosterhuis B, et al. Rational experimental design for bioanalytical methods validation. Illustration using an assay method for total captopril in plasma. J Chromatogr A 1996;730(1-2):381-94.
24. Kringle R, Hoffman D. Stability methods for assessing stability of compounds in whole blood for clinical bioanalysis. Drug Inf J 2001;35:1261-70.
25. Viswanathan CT, Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, et al. Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays. AAPS J 2007;9(2):E260-7.
26. Singh PS, Shah G. Analytical method development and validation. J Pharm Res 2011;4(5):2330-2.
27. Dadgar D, Burnett PE. Issues in evaluation of bioanalytical method selectivity and drug stability. J Pharm Biomed Anal 1995;14(1-2):23-31.
28. Miller KJ, Bowsher RR, Celniker A, Gibbons J, Gupta S, Lee JW, et al. Workshop on bioanalytical methods validation for macromolecules: Summary report. Pharm Res 2001;18(9):1373-83.
29. Hubert H, Chiap P, Crommen J, Boulanger B, Chapuzet E, Mercier N, et al. The SFSTP guide on the validation of chromatographic methods for drug analysis: From the Washington Conference to the laboratory. Anal Chim Acta 1999;391:45-55.
30. Timm U, Wall M, Dell D. A new approach for dealing with the stability of drugs in biological fluids. J Pharm Sci 1985;74(9):972-7.
31. Nowatzke W, Woolf E. Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samples. AAPS J 2007;9(2):E117-22.
32. Braggio S, Barnaby RJ, Grossi P, Cugola M. A strategy for validation of bioanalytical methods. J Pharm Biomed Anal 1996;14(4):375-88.
33. James CA, Breda M, Frigerio E. Bioanalytical method validation: Arisk-based approach? J Pharm Biomed Anal 2004;35(4):887-93.
34. Boulanger B, Chiap P, Dewe W, Crommen J, Hubert P. An analysis of the SFSTP guide on validation of chromatographic bioanalytical methods: Progresses and limitations. J Pharm Biomed Anal 2005;32(4-5):753-65.